Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

188.42
+5.022.74%
Post-market: 190.001.58+0.84%19:24 EDT
Volume:2.76M
Turnover:525.69M
Market Cap:292.24B
PE:28.81
High:192.97
Open:190.88
Low:187.95
Close:183.40
52wk High:212.71
52wk Low:122.48
Shares:1.55B
Float Shares:1.54B
Volume Ratio:1.53
T/O Rate:0.18%
Dividend:3.14
Dividend Rate:1.66%
EPS(TTM):6.54
EPS(LYR):6.54
ROE:22.84%
ROA:8.19%
PB:6.00
PE(LYR):28.81

Loading ...

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Economic Data Deluge

MT Newswires Live
·
Feb 10

U.S. Stock Futures Advance Ahead of Retail Sales Data; Treasury Yields Signal Rate Cut Bets

Stock News
·
Feb 10

Press Release: AstraZeneca results: FY and Q4 2025

Dow Jones
·
Feb 10

BUZZ-Tectonic shares plunge as AstraZeneca scraps rival relaxin drug

Reuters
·
Feb 10

AstraZeneca (AZN) Receives a Buy from UBS

TIPRANKS
·
Feb 10

Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)

TIPRANKS
·
Feb 10

These Stocks Are Today's Movers: Spotify, AppLovin, TSMC, BP, ON Semi, Credo, Upwork, and More -- Barrons.com

Dow Jones
·
Feb 10

U.S. Stocks to Watch: AppLovin, TSMC, BP, ON Semi, Credo, Upwork, ZoomInfo, and More

Dow Jones
·
Feb 10

AstraZeneca Forecasts Steady Growth In 2026 On Strong Cancer Drug Demand, Shares Rise

Reuters
·
Feb 10

AstraZeneca CEO teases weight-loss drug candidate as profit meets target

Dow Jones
·
Feb 10

J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Feb 10

AstraZeneca Projects Double-Digit EPS Growth Following $18.5 Billion CSPC Pharma Partnership

Deep News
·
Feb 10

AstraZeneca Forecasts Mid-to-High Single-Digit Revenue Growth And Low Double-Digit Core EPS Increase For FY 2026, With Core Tax Rate Between 18%-22%

Benzinga
·
Feb 10

AstraZeneca Q4 Adj. EPS $2.12 Beats $2.09 Estimate, Sales $15.503B Beat $15.490B Estimate

Benzinga
·
Feb 10

AstraZeneca Forecasts Growth in 2026 as It Builds Drug Pipeline

Reuters
·
Feb 10

AstraZeneca PLC Stock Falls Monday, Underperforms Market

Dow Jones
·
Feb 10

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 09

AstraZeneca's Weight-Loss Drug Strategy in Focus -- Earnings Preview

Dow Jones
·
Feb 09

Joint Vaccine Venture Between Kangtai Biological and AstraZeneca Terminated Following Market Shifts

Deep News
·
Feb 08

TrumpRx Is Here. Most People Won't Benefit. -- Barrons.com

Dow Jones
·
Feb 07